(HealthDay)—A category of diabetes medication, known as sodium-glucose co-transporter-2 (SGLT2) inhibitors, shield towards kidney illness in sufferers with sort 2 diabetes, in accordance with a evaluate revealed on-line Sept. 5 in The Lancet Diabetes & Endocrinology.
Brendon L. Neuen, M.B.B.S., from the College of New South Wales in Sydney, and colleagues carried out a scientific literature evaluate to determine randomized, managed trials of SGLT2 inhibitors that reported results on main kidney outcomes in individuals with sort 2 diabetes.
The researchers recognized 4 research that assessed three SGLT2 inhibitors: empagliflozin, canagliflozin, and dapagliflozin. Amongst 38,723 members, the researchers discovered that 252 sufferers required dialysis, transplantation, or died of kidney illness; 335 developed end-stage kidney illness; and 943 had acute kidney injury. There was a considerable discount within the danger of dialysis, transplantation, or demise attributable to kidney illness (relative danger, zero.67) with SGLT2 inhibitors. There was additionally a discount in end-stage kidney disease (relative danger, zero.65) and acute kidney damage (relative danger, zero.75) with SGLT2 inhibitors. A profit was seen for all estimated glomerular filtration price and albuminuria subgroups.
“These information present substantive proof supporting using SGLT2 inhibitors to forestall main kidney outcomes in individuals with sort 2 diabetes,” the authors write.
A number of authors disclosed monetary ties to the pharmaceutical trade.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2019 HealthDay. All rights reserved.
SGLT2 inhibitors shield towards kidney illness in T2DM (2019, October 11)
retrieved 11 October 2019
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.